Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.

ABSTRACT:

Purpose

Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label study in which patients with solid tumors harboring IDH1/2 mutations were treated with olaparib as monotherapy, with objective response and clinical benefit rates as the primary end points.

Methods

Ten patients with IDH1/2-mutant tumors by next-generation sequencing were treated with olaparib 300 mg twice daily.

Results

Three of five patients with chondrosarcomas had clinical benefit, including one patient with a partial response and two with stable disease lasting > 7 months. A patient with pulmonary epithelioid hemangioendothelioma had st

SUBMITTER: Eder JP 

PROVIDER: S-EPMC9848565 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature